235 related articles for article (PubMed ID: 38031192)
1. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
Dolinska M; Cai H; Månsson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson AS; Deneberg S; Söderlund S; Jädersten M; Ungerstedt J; Tobiasson M; Östman A; Mustjoki S; Stenke L; Le Blanc K; Hellström-Lindberg E; Lehmann S; Ekblom M; Olsson-Strömberg U; Sigvardsson M; Qian H
Blood; 2023 Jul; 142(1):73-89. PubMed ID: 37018663
[TBL] [Abstract][Full Text] [Related]
3. Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
Feng H; Fu Y; Cui Z; Zhou M; Zhang L; Gao Z; Ma S; Chen C
Br J Haematol; 2023 Sep; 202(6):1178-1191. PubMed ID: 37469124
[TBL] [Abstract][Full Text] [Related]
4. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
Okabe S; Moriyama M; Gotoh A
Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
[TBL] [Abstract][Full Text] [Related]
5. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
Khorashad JS; Eiring AM; Mason CC; Gantz KC; Bowler AD; Redwine HM; Yu F; Kraft IL; Pomicter AD; Reynolds KR; Iovino AJ; Zabriskie MS; Heaton WL; Tantravahi SK; Kauffman M; Shacham S; Chenchik A; Bonneau K; Ullman KS; O'Hare T; Deininger MW
Blood; 2015 Mar; 125(11):1772-81. PubMed ID: 25573989
[TBL] [Abstract][Full Text] [Related]
6. Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSCs) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs.
Benjamin ESB; Vinod E; Illangeswaran RSS; Rajamani BM; Vidhyadharan RT; Bagchi A; Maity A; Mohan A; Parasuraman G; Amirtham SM; Abraham A; Velayudhan SR; Balasubramanian P
Cell Signal; 2024 Apr; 116():111067. PubMed ID: 38281615
[TBL] [Abstract][Full Text] [Related]
7. Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells.
Rattigan KM; Brabcova Z; Sarnello D; Zarou MM; Roy K; Kwan R; de Beauchamp L; Dawson A; Ianniciello A; Khalaf A; Kalkman ER; Scott MT; Dunn K; Sumpton D; Michie AM; Copland M; Tardito S; Gottlieb E; Vignir Helgason G
Nat Commun; 2023 Aug; 14(1):4634. PubMed ID: 37591854
[TBL] [Abstract][Full Text] [Related]
8. Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.
Wu A; Liu X; Fruhstorfer C; Jiang X
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542279
[TBL] [Abstract][Full Text] [Related]
9. Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid Leukemia through Advanced Non-Invasive Apoptosis Detection Sensor Version 2 Detection.
Lee CH; Hsu KW; Hsieh YY; Li WT; Long Y; Lin CY; Chen SH
Cells; 2024 Apr; 13(7):. PubMed ID: 38607055
[TBL] [Abstract][Full Text] [Related]
10. Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance.
Truitt L; Hutchinson C; DeCoteau JF; Geyer CR
Oncogenesis; 2014 Oct; 3(10):e122. PubMed ID: 25329721
[TBL] [Abstract][Full Text] [Related]
11. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.
Bhatia S; Diedrich D; Frieg B; Ahlert H; Stein S; Bopp B; Lang F; Zang T; Kröger T; Ernst T; Kögler G; Krieg A; Lüdeke S; Kunkel H; Rodrigues Moita AJ; Kassack MU; Marquardt V; Opitz FV; Oldenburg M; Remke M; Babor F; Grez M; Hochhaus A; Borkhardt A; Groth G; Nagel-Steger L; Jose J; Kurz T; Gohlke H; Hansen FK; Hauer J
Blood; 2018 Jul; 132(3):307-320. PubMed ID: 29724897
[TBL] [Abstract][Full Text] [Related]
12. c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model.
Ye Y; Yang X; Li F; Liu W; Zhang W; Huang Z
Animal Model Exp Med; 2024 Apr; 7(2):136-144. PubMed ID: 36300552
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors.
Costa A; Scalzulli E; Carmosino I; Ielo C; Bisegna ML; Martelli M; Breccia M
Expert Opin Pharmacother; 2024 Feb; 25(2):189-202. PubMed ID: 38488824
[TBL] [Abstract][Full Text] [Related]
14. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML.
Vetrie D; Helgason GV; Copland M
Nat Rev Cancer; 2020 Mar; 20(3):158-173. PubMed ID: 31907378
[TBL] [Abstract][Full Text] [Related]
15. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.
Haddad FG; Kantarjian H
J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394773
[TBL] [Abstract][Full Text] [Related]
16. Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.
Bencomo-Alvarez AE; Rubio AJ; Olivas IM; Gonzalez MA; Ellwood R; Fiol CR; Eide CA; Lara JJ; Barreto-Vargas C; Jave-Suarez LF; Nteliopoulos G; Reid AG; Milojkovic D; Druker BJ; Apperley J; Khorashad JS; Eiring AM
Oncogene; 2021 Apr; 40(15):2697-2710. PubMed ID: 33712704
[TBL] [Abstract][Full Text] [Related]
17. Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells.
Qiu S; Sheth V; Yan C; Liu J; Chacko BK; Li H; Crossman DK; Fortmann SD; Aryal S; Rennhack A; Grant MB; Welner RS; Paterson AJ; Wende AR; Darley-Usmar VM; Lu R; Locasale JW; Bhatia R
Blood; 2023 Aug; 142(6):574-588. PubMed ID: 37192295
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Ismail MA; Vezzalini M; Morsi H; Abujaber A; Al Sayab A; Siveen K; Yassin MA; Monne M; Samara M; Cook R; Sorio C; Modjtahedi H; Al-Dewik NI
Sci Rep; 2021 Apr; 11(1):8833. PubMed ID: 33893334
[TBL] [Abstract][Full Text] [Related]
19. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.
Krishnan V; Schmidt F; Nawaz Z; Venkatesh PN; Lee KL; Ren X; Chan ZE; Yu M; Makheja M; Rayan NA; Lim MGL; Cheung AMS; Bari S; Chng WJ; Than H; Ouyang J; Rackham O; Tan TZ; Hwang WYK; Chuah C; Prabhakar S; Ong ST
Blood; 2023 Jun; 141(22):2738-2755. PubMed ID: 36857629
[TBL] [Abstract][Full Text] [Related]
20. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.
Järås M; Johnels P; Hansen N; Agerstam H; Tsapogas P; Rissler M; Lassen C; Olofsson T; Bjerrum OW; Richter J; Fioretos T
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16280-5. PubMed ID: 20805474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
